Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

The Lancet Oncology

Volumn 19, Issue 5, 2018, Pages 672-681

  Long, Georgina V ^a,b   Atkinson, Victoria ^c   Lo, Serigne ^a   Sandhu, Shahneen ^d   Guminski, Alexander D ^a,b   Brown, Michael P ^e   Wilmott, James S ^a   Edwards, Jarem ^a   Gonzalez, Maria ^a   Scolyer, Richard A ^a,f   Menzies, Alexander M ^a,b   McArthur, Grant A ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Royal North Shore and Manly Hospitals   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ADVERSE EVENT; AGED; ARTHRALGIA; ARTICLE; AUSTRALIA; BRAIN METASTASIS; COLITIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPITUITARISM; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MONOTHERAPY; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEPHRITIS; NEUTROPENIA; OPEN STUDY; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEIZURE; SURVIVAL ANALYSIS; THYROIDITIS; VITILIGO; VOMITING; XEROSTOMIA; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; SKIN TUMOR; TIME FACTOR;

AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; BRAIN NEOPLASMS; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NIVOLUMAB; PROGRESSION-FREE SURVIVAL; SKIN NEOPLASMS; TIME FACTORS;

EID: 85044595615     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30139-6     Document Type: Article

References (17)

1. Davies, MA, Liu, P, McIntyre, S, et al. Prognostic Factors for survival in melanoma patients with brain metastases. Cancer 117 (2011), 1687–1696.
2. Fife, KM, Colman, MH, Stevens, GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22 (2004), 1293–1300.
3. Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377 (2017), 1345–1356.
4. V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17 (2016), 1248–1260.
5. Long, GV, Stroyakovskiy, D, Gogas, H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
6. Robert, C, Karaszewska, B, Schachter, J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
7. Robert, C, Schachter, J, Long, GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
8. V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18 (2017), 863–873.
9. Long, GV, Trefzer, U, Davies, MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 1087–1095.
10. McArthur, GA, Maio, M, Arance, A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28 (2017), 634–641.
11. Goldberg, SB, Gettinger, SN, Mahajan, A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17 (2016), 976–983.
12. Eisenhauer, EA, Therasse, P, Boggaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
13. Hayward, NK, Wilmott, JS, Waddell, N, et al. Whole-genome landscapes of major melanoma subtypes. Nature 545 (2017), 175–180.
14. Hugo, W, Shi, H, Sun, L, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162 (2015), 1271–1285.
15. Kakavand, H, Wilmott, JS, Menzies, AM, et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res 21 (2015), 3140–3148.
16. Domingues Pires da Silva, IE, Johnpulle, RAN, Banks, PD, et al. Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). Proc Am Soc Clin Oncol, 35(suppl), 2017, 9513 (abstr).
17. Tawbi, HA-H, Forsyth, PAJ, Algazi, AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. Proc Am Soc Clin Oncol, 35(suppl), 2017, 9507 (abstr).